CSL Vifor And Travere Therapeutics Granted European Commission Conditional Marketing Authorization For FILSPARI (Sparsentan) For The Treatment Of IgA Nephropathy
First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe
Conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial